FUSN vs. INBX, BEAM, DNA, ADMA, RXRX, NMRA, TARS, SANA, APGE, and FDMT
Should you be buying Fusion Pharmaceuticals stock or one of its competitors? The main competitors of Fusion Pharmaceuticals include Inhibrx (INBX), Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA), ADMA Biologics (ADMA), Recursion Pharmaceuticals (RXRX), Neumora Therapeutics (NMRA), Tarsus Pharmaceuticals (TARS), Sana Biotechnology (SANA), Apogee Therapeutics (APGE), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "biological products, except diagnostic" industry.
Fusion Pharmaceuticals (NASDAQ:FUSN) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
72.9% of Fusion Pharmaceuticals shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 7.8% of Fusion Pharmaceuticals shares are held by company insiders. Comparatively, 25.8% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Fusion Pharmaceuticals has a net margin of -4,136.55% compared to Inhibrx's net margin of -13,408.95%. Fusion Pharmaceuticals' return on equity of -48.74% beat Inhibrx's return on equity.
Fusion Pharmaceuticals has higher revenue and earnings than Inhibrx. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
Fusion Pharmaceuticals has a beta of -0.69, suggesting that its share price is 169% less volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500.
In the previous week, Fusion Pharmaceuticals had 6 more articles in the media than Inhibrx. MarketBeat recorded 11 mentions for Fusion Pharmaceuticals and 5 mentions for Inhibrx. Inhibrx's average media sentiment score of 0.47 beat Fusion Pharmaceuticals' score of 0.23 indicating that Inhibrx is being referred to more favorably in the news media.
Fusion Pharmaceuticals presently has a consensus price target of $20.25, suggesting a potential downside of 5.51%. Inhibrx has a consensus price target of $27.00, suggesting a potential downside of 20.91%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Fusion Pharmaceuticals is more favorable than Inhibrx.
Fusion Pharmaceuticals received 10 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
Summary
Fusion Pharmaceuticals beats Inhibrx on 12 of the 18 factors compared between the two stocks.
Get Fusion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FUSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Pharmaceuticals Competitors List
Related Companies and Tools
